US FDA Rejection Stings Nucala In COPD; New Study May Be Needed
Executive Summary
Mepolizumab would be first drug for chronic obstructive pulmonary disorder to use eosinophil count as a biomarker, but FDA’s complete response letter says more clinical data are needed.
You may also be interested in...
Dupixent Heralds The Age Of Biologics In COPD
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.
AstraZeneca Looks To Challenge GSK’s Nucala With Fasenra EGPA Data
AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.
Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation
The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.